Log in to search using one of your social media accounts:

 

Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension
New Investor Takeda Ventures Joins Syndicate; Proceeds to Fund Lead Clinical Stage Program for the Treatment of Overactive Bladder and Irritable Bowel Syndrome INDIANAPOLIS and LONDON, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Outpost ... Biopharmaceuticals, Venture Capital, Personnel Outpost Medicine, Irritable Bowel Syndrome, Overactive Bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Axonics IDE trial for r-SNM neuromod
Axonics Modulation Technologies said today it won FDA investigational device exemption clearance to engage in a pivotal study of its r-SNM rechargeable sacral neuromodulation system designed for treating overactive bladder and bowel dysfunction. The Irvine, Calif.-based company said it expects to begin enrolling patients in the clinical study in November, aiming to enlist 120 patients at 15 centers in the US and Western Europe. “During 2017, as part of the IDE process, the FDA conducted a significant review of our product. A major focus of the technical review was the long-term safety of our implant. The fact th...
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Axonics Modulation Technologies Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: CommercialTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Prostate problem? Take 2 nuts
By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life. Traditional doctors give you two choices. Go under the knife or you take Big Pharma’s drugs. Either way, you have a good chance of ending up with your manhood on the line… If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1 Big Pharma’s meds to shrink your prostate are no better. These sy...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Are your medications affecting your memory?
Many of today’s most popular drugs can make you forgetful. They inhibit your brain’s chemical messengers. And this blocks your concentration, memory and ability to focus. More specifically, these drugs block the activity of a neurotransmitter in your brain called acetylcholine. Acetylcholine is directly involved in learning and memory. And blocking it is a risky business… I’ve seen confusion, memory loss, and declining mental skills in patients who take these drugs. New research confirms what I see in my own practice. One recent study found that people taking these kinds of drugs had shrunken ar...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Cogentix backs Vensica Medical and its needle-free drug delivery system
Cogentix Medical (NASDAQ: CGNT) said today that it invested $2 million in privately-held Vensica Medical and its ultrasound-based, needle-free drug delivery device, VensiCare. Israel-based Vensica Medical is developing its VensiCare device as a way to deliver botulinum toxin to treat overactive bladder. The company also has IP for the delivery of oncology agents to the bladder, according to Cogentix. Get the full story at our sister site, Drug Delivery Business News. The post Cogentix backs Vensica Medical and its needle-free drug delivery system appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 28, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Wall Street Beat Cogentix Medical vensicamedical Source Type: news

Tackling bedwetting: ‘Don’t be afraid to talk about it’
Bedwetting, otherwise known as urinary incontinence or enuresis, is fairly common, often embarrassing and sometimes difficult to talk about. It is estimated that about 20 percent of boys and 17 percent of girls, ages 6 to 7 years old have some problem with daytime or nighttime wetting. Still, many kids are reluctant to talk about wetting with parents, friends and teachers. Parents themselves often have a hard time confronting the issue. The Voiding Improvement Program (VIP) at Boston Children’s Hospital offers a comprehensive approach to bedwetting tailored to each child’s individual needs. &ldqu...
Source: Thrive, Children's Hospital Boston - August 7, 2017 Category: Pediatrics Authors: Maureen McCarthy Tags: Health & Wellness bedwetting Dr. Carlos Estrada enuresis Pamela Kelly Voiding Improvement Program Source Type: news

Boston Scientific joins OAB device dev Amphora Medical ’ s $36m Series B
Amphora Medical said today it closed a $35.5 million Series B financing round, led by major medtech player Boston Scientific (NYSE:BSX), with funds slated to support a US pivotal trial of its Selective Bladder Denervation System for treating women with overactive bladder. Amphora’s Selective Bladder Denervation System is a minimally-invasive, cystopic device which uses targeted ablation to reduce nerve signals responsible for OAB symptoms at their source without harming nerves responsible for normal bladder function, the Minneapolis, Minn.-based company said. “The closing of this round is an important mile...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology Women's Health Amphora Medical Boston Scientific Source Type: news

Boston Scientific joins in $36M round for Twin Cities med-tech startup
Amphora Medical Inc. is developing a device to treat overactive bladder and will put the capital toward a clinical trial. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 21, 2017 Category: Health Management Authors: Katharine Grayson Source Type: news

Boston Scientific joins in $36M round for Twin Cities med-tech startup
Amphora Medical Inc. is developing a device to treat overactive bladder and will put the capital toward a clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 21, 2017 Category: Biotechnology Authors: Katharine Grayson Source Type: news

The Role of the Female Urinary Microbiota in OAB Symptoms The Role of the Female Urinary Microbiota in OAB Symptoms
New research suggests a possible link between the microbiota of the female urinary tract and overactive bladder symptoms. What are the implications for urine culturing practices?Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2017 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. OrthoSensor raises $6.3m OrthoSensor raised $6.3 million in a new round of mixed financing, according to an SEC filing posted this week. Money in the round came from 15 unnamed sources, according to the SEC filing, with the 1st...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic touts 5-year data on InterStim neuromod device for OAB
Medtronic (NYSE:MDT) today touted 5-year results from the InSite study of its InterStim neuromodulation treatment for overactive bladder syndrome. InterStim is designed to stimulate the sacral nerve to treat OAB, meaning urinary urge incontinence and/or urgency-frequency. The InSite study enrolled 340 patients, of which 272 were implanted with an InterStim device, comparing treatment with the device with standard drug therapy. The primary safety endpoint was to “demonstrate that the upper bound of the 95% CI for the cumulative five-year rate of adverse events related to the tined lead that require surgery is les...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Urology Women's Health Medtronic Source Type: news

Axonics adds $21m to Series C round
Axonics Modulation Technologies said today that it put another $21 million in its coffers in the second tranche of a Series C round for its sacral nerve modulation technology in treating overactive bladder syndrome. The first, $15 million Series C tranche closed in May. The latest, $20.5 million tranche takes Axonics’ total raise to at least $106.1 million, adding to its $32.6 million Series A round and the $38.5 million Series B. The Irvine, Calif.-based company said it plans to use the proceeds on a pivotal study that’s slated to launch late this year. The Series C second tranche included ...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

USFDA gives nod to Zydus Cadila's overactive bladder tablets
The drug is used to take care of an overactive bladder and urinary incontinence and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 28, 2017 Category: Pharmaceuticals Source Type: news

Glenmark Pharma's overactive bladder drug gets USFDA nod
According to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 22, 2017 Category: Pharmaceuticals Source Type: news

Stop an overactive bladder with these 7 herbs and supplements
(Natural News) Guidelines developed by the American Urological Association call for lifestyle and behavioral changes as primary treatments for an overactive bladder. People with an overactive bladder should opt for natural remedies such as dietary changes and fluid management. Patients may also try learning bladder control techniques such as scheduled, delayed, and double-void urination. The guidelines... (Source: NaturalNews.com)
Source: NaturalNews.com - May 11, 2017 Category: Consumer Health News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 2, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Advanced Cardiac Therapies lands $45m round led by new PE shop Ajax Health Ajax Health, the medical device portfolio management company newly formed by KKR and Aisling Capital, led a $45 million round for Advanced Cardiac Thera...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Axonics raises another $15m for U.S. sacral neurostim trial
Axonics Modulation Technologies said today that it put nearly $15 million into its coffers as it readies a pivotal study later this year for its sacral nerve modulation technology in treating overactive bladder syndrome. The Irvine, Calif.-based company said it hopes to add another $15.5 million to the $14.5 million it pulled in from its Series C round, which involved all of its major backers including Edmond de Rothschild Investment Partners, Advent Life Sciences, Cormorant Asset Management, Legend Capital, NeoMed Management and “a select group of private individuals.” “These world-cl...
Source: Mass Device - May 2, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news

Medical News Today: How to treat an overactive bladder with natural remedies
In this article, learn about the symptoms of an overactive bladder, when a doctor should be consulted, and natural remedies to treat an overactive bladder. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 24, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Medical News Today: Overactive bladder in children: Causes, symptoms, and treatment
Learn about the factors that can lead to an overactive bladder in children. What are the signs and when should treatment be given for this condition? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 18, 2017 Category: Consumer Health News Tags: Pediatrics / Children's Health Source Type: news

Medical News Today: Overactive bladder in men: What causes it and how is it treated?
Overactive bladder is a urinary disorder that can affect men and women. What are the causes in men and can lifestyle changes or medical treatments help? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 18, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Depressive Disorders Up With Antimuscarinics for OAB
Increased risk for women with overactive bladder syndrome receiving antimuscarinics (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 13, 2017 Category: Psychiatry Tags: Family Medicine, Gynecology, Internal Medicine, Nursing, Pharmacy, Psychiatry, Urology, Journal, Source Type: news

Medical News Today: Best treatments for an overactive bladder
Learn about different treatment options for an overactive bladder, such as dietary and lifestyle changes. Also learn how to monitor an overactive bladder. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Medical News Today: How to manage nocturia: Treating an overactive bladder at night
In this article, we look at the causes of nocturia, which causes frequent urination at night. Learn about how to prevent it and get a good night's sleep. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Medical News Today: Best medications to treat overactive bladder
In this article, learn about the initial treatments for an overactive bladder, which medications may be used, and what further treatment may help. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Drug for overactive bladder linked to depression
A recent study found a drug used to treat overactive bladder in women significantly increased the risk of developing depression within three years. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 5, 2017 Category: Consumer Health News Source Type: news

Overactive bladder drug linked with increased risk of depression
(Wiley) A recent study found that women with overactive bladder who received antimuscarinics were 38 percent more likely to be diagnosed with depressive disorder within the next three years than those who did not receive antimuscarinics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2017 Category: Global & Universal Source Type: news

Drug Tied to Dementia Risk Overprescribed to Seniors
Lower cost might help drive doctors' choice, researchers say Source: HealthDay Related MedlinePlus Pages: Dementia, Overactive Bladder, Seniors' Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 31, 2017 Category: Consumer Health News Source Type: news

Drug Tied to Dementia Risk Overprescribed to Seniors: Study
Lower cost might help drive doctors' choice, researchers say Source: HealthDay Related MedlinePlus Pages: Dementia, Overactive Bladder, Seniors' Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 31, 2017 Category: Consumer Health News Source Type: news

Drug Tied to Dementia Risk Overprescribed to Seniors: Study
THURSDAY, March 30, 2017 -- A drug linked to a raised risk of dementia is taken by millions of older Americans who have an overactive bladder, researchers say. More than one-quarter of patients with the urinary problem had been prescribed the drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 30, 2017 Category: Journals (General) Source Type: news

Medical News Today: Overactive bladder: Signs and symptoms
What is an overactive bladder and are there any risk factors? When should a doctor be consulted and can lifestyle changes or medication help as treatments? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 30, 2017 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Concern over high US prescribing levels of common drug linked to dementia
A new analysis raises concern over high prescription rates in the USA of a common drug used to treat overactive bladder. The drug, oxybutynin, when taken orally, is consistently linked with cognitive impairment and dementia in the elderly. The analysis shows that oxybutynin, is prescribed in more than a quarter of cases of overactive bladder (27.3%), even though other more suitable drugs are available. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Better Adherence With Mirabegron in Patients With Overactive Bladder Better Adherence With Mirabegron in Patients With Overactive Bladder
Patients with overactive bladder (OAB) are more likely to obtain and keep using mirabegron versus antimuscarinic agents, according to a retrospective study in UK clinical practice.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 1, 2017 Category: Surgery Tags: Urology News Source Type: news

Axonics wins Health Canada nod for rechargeable sacral neuromod system
Axonics Modulation Technologies said today it won Health Canada approval for its rechargeable Sacral Neuromodulation System designed to treat overactive bladder, fecal incontinence and urinary retention. The Irvine, Calif.-based company said it expects to be treating patients with the device during the 1st quarter of this year. “The Health Canada approval provides Axonics with another important marketing approval. Along with our European CE mark, it gives us the ability to sell our r-SNM System in 2 large international territories. Additionally, we anticipate IDE clearance from the US FDA to treat patients ...
Source: Mass Device - January 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Regulatory/Compliance Axonics Modulation Technologies Source Type: news

MassDevice.com +5 | The top 5 medtech stories for December 16, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Milestone Scientific prices $3m round Milestone Scientific‘s today priced an upcoming offering, looking to raise approximately $3 million. The Livingston, N.J.-based company said it plans to offer 2 million shares of comm...
Source: Mass Device - December 16, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news

StimGuard launches OAB neurostim trial
StimGuard said today it enrolled the 1st patient in a clinical trial of its StimGuard miniature implantable device designed to treat urinary incontinence resulting from refractory overactive bladder syndrome. The Fort Lauderdale, Fla.-based company’s system is implanted at the tibial nerve through a needle-sized introducer and uses wireless technology to stimulate the nerve and treat the symptoms of overactive bladder. “If successfully trialed, the StimGuard technology would allow neuromodulation to be offered to patients in an office setting, which has never been the case before for a permanent, long-term...
Source: Mass Device - December 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neuromodulation/Neurostimulation StimGuard Source Type: news

Siteless: The Future of Clinical Trials?
This article is extracted fromTrends in Clinical Data& Technology. To download the magazine, clickhere.Related Content: The Patient Data Gold RushMeeting the Information Needs of PatientsTurning Clinical Trial Recruitment on its HeadConnecting with Patients via Compelling ContentPrimary Event: Data Quality and Technology in Clinical Trials USAPr écis: Clinical trials are moving out of the clinic and into patients ’ own homes.Premium`: Freemium`: Channels: ClinicalTags: Clinical DataClinical DevelopmentClinical Trial RecruitmentClinical Trial SoftwareClinical TrialsChannel...
Source: EyeForPharma - November 17, 2016 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

Is Overactive Bladder Real?
(MedPage Today) -- Marketing or medicine: which is it? (Source: MedPage Today Urology)
Source: MedPage Today Urology - November 2, 2016 Category: Urology & Nephrology Source Type: news

Botox May Top Neuromodulation in Overactive Bladder Botox May Top Neuromodulation in Overactive Bladder
Episodes of urinary urgency were slightly lower after onabotulinumtoxinA injections, but the treatment led to more urinary tract infections and self-catheterizations in a randomized controlled trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2016 Category: Consumer Health News Tags: Urology News Source Type: news

Eisai launches Uritos tablets to treat overactive bladder in Thailand
Pharmaceutical company Eisai has launched Uritos tablets (imidafenacin) to treat overactive bladder (OAB), in Thailand. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 4, 2016 Category: Pharmaceuticals Source Type: news

Bluewind Medical wins CE Mark for Vivendi mini-neurostim pain implant
Neurostim developer Bluewind Medical said today it won CE Mark approval in the European Union for its Vivendi neurostimulation device designed to treat peripheral neuropathic pain. The newly cleared neurostim device is 90% smaller than ‘typical’ neurostimulators on the market, the Israeli company said, and is designed to be implanted in close proximity to the Tibial nerve so it can apply electrical stimulation to the nerve to ease or mask pain. “This new treatment paradigm, transforms the way patients are treated today, relieves them from the need for Opioid or other pharmacological treatments and al...
Source: Mass Device - September 7, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Pain Management Regulatory/Compliance Bluewind Medical Source Type: news

Cipla gets USFDA nod for overactive bladder treating drug
"We have received final approval for ANDA for Darifenacin extended-release tablets, 7.5 mg and 15mg, from USFDA," a company statement said here. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2016 Category: Pharmaceuticals Source Type: news

"It's A Scandal" -Daryl Hall on Doctors Denying Chronic Lyme
Growing up a musically-obsessed child in the 80's, Daryl Hall was one of my biggest inspirations. A masterful, inventive songwriter with an ocean of soul, he set me on the path to being an artist, to never waste a word, and to sing because I mean it. With six number ones and five additional top ten hits throughout the 70's and 80's Daryl Hall and John Oates are the number one duo in music history. Still at the top of his game at 69 years old, Daryl has won legions of new fans with his hit MTV Live show Live From Daryl's House. In February of 2015, at my very sickest from chronic Lyme and Bartonella, after it was missed b...
Source: Science - The Huffington Post - July 22, 2016 Category: Science Source Type: news

Vensica Medical Completes $500,000 Finance Round
MISGAV, Israel, July 19, 2016 -- (Healthcare Sales & Marketing Network) -- Vensica Medical, a portfolio company of Trendlines Medical, announced the completion of a financing round of US$500,000 from a private foreign investor. Vensica is developing a ne... Devices, Drug Delivery, Urology, Venture CapitalVensica Medical, overactive bladder, Botox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 19, 2016 Category: Pharmaceuticals Source Type: news

Darin Hammers Appointed President And CEO Of Cogentix Medical, Inc.
MINNEAPOLIS, July 12, 2016 -- (Healthcare Sales & Marketing Network) -- Cogentix Medical, Inc. (CGNT), a global medical device company with innovative and proprietary products serving urology and airway management markets, today announced that Darin Hamme... Devices, Urology, PersonnelCogentix Medical, EndoSheath, overactive bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2016 Category: Pharmaceuticals Source Type: news

Researchers identify bacterial infection as a possible cause of bladder condition
A research team has identified bacterial infection as a possible cause of Overactive Bladder Syndrome (OAB). OAB is a condition where the bladder muscle spontaneously contracts before the bladder is full. In the USA, it is ranked in the top 10 of common chronic conditions, competing with both diabetes and depression, with a reported prevalence of up to 31-42% in the adult population. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 7, 2016 Category: Science Source Type: news

Understanding how chemical changes in the brain affect Alzheimer's disease
A new study is helping to explain why the long-term use of common anticholinergic drugs used to treat conditions like allergies and overactive bladder lead to an increased risk of developing dementia later in life. The study used mouse models to show that long-term suppression of the neurotransmitter acetylcholine -- a target for anticholinergic drugs -- results in dementia-like changes in the brain. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 22, 2016 Category: Science Source Type: news

Understanding how chemical changes in the brain affect Alzheimer's disease
(University of Western Ontario) A new study from Western University is helping to explain why the long-term use of common anticholinergic drugs used to treat conditions like allergies and overactive bladder lead to an increased risk of developing dementia later in life. The study used mouse models to show that long-term suppression of the neurotransmitter acetylcholine -- a target for anticholinergic drugs -- results in dementia-like changes in the brain. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2016 Category: Global & Universal Source Type: news

Axonics launches post-market sacral neuromod OAB study
Axonics Modulation Technologies said today it launched the Relax-OAB 65-patient post-market clinical follow-up study of its SNM system designed to treat overactive bladder. The SNM rechargeable neuromod system is designed to treat overactive bladder, urinary retention and fecal incontinence through sacral nerve stimulation, the Irvine, Calif.-based company said. Axonics touted the 1st implants and enrollments in the study, which took place at London’s National Hospital for Neurology and Neurosurgery and the Netherlands’ Maastricht University Medical Centre. “This miniaturized rechargeable SNM System repre...
Source: Mass Device - June 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neuromodulation/Neurostimulation Urology Axonics Modulation Technologies Source Type: news